<DOC>
	<DOC>NCT01526837</DOC>
	<brief_summary>This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.</brief_summary>
	<brief_title>Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1. Recurrent Glioblastoma 2. At least 12 weeks expected survival (KPS &gt;60) 3. 18 years of age or older 4. Able and willing to participate 1. Any prior diagnosis of any other cancer or other concurrent malignancy. 2. Planned use or current use of other investigation therapy. 3. Systemic autoimmune disease 4. HIV positive 5. Concurrent life threatening disease 6. Impaired organ function 7. Active infection 8. Inadequately controlled hypertension 9. Congestive heart failure 10. Myocardial infection/unstable angina within 6 months 11. Stroke within 6 months 12. Pheripheral vascular disease 13. History of abdominal fistula/gastrointestinal performation 14. Nonhealing wound 15. Coagulation disease 16. Known allergy to study treatments 17. Pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Brain tumor</keyword>
	<keyword>GBM</keyword>
	<keyword>Brain cancer</keyword>
</DOC>